Sign In
Buy BVNKF
$27.69
+0 (+0%)
At Close: Jul 31, 2026
Bavarian Nordic A/S (BVNKF) Q1 2025 Earnings Call Transcript
01:53pm, Friday, 09'th May 2025
Bavarian Nordic A/S (OTCPK:BVNKF) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Rolf Sass Sorensen - Head, Investor Relations Paul Chaplin - Chief Executive Officer Henr
Bavarian Nordic's Chikungunya Vaccine Receives Recommendation from U.S. CDC's Advisory Committee on Immunization Practices (ACIP)
04:04pm, Wednesday, 16'th Apr 2025
COPENHAGEN, Denmark, April 16, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (A
Correction: Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S
12:02pm, Wednesday, 09'th Apr 2025
COPENHAGEN, Denmark, April 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors'
Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S
11:38am, Wednesday, 09'th Apr 2025
COPENHAGEN, Denmark, April 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors'
Bavarian Nordic Trading At Great Value Levels With Upbeat 2025 Outlook
04:45pm, Monday, 07'th Apr 2025
BVNKF now expects margin improvements from rabies/TBE vaccine production transfers to Denmark, starting in 2025. Also, their recently FDA-approved freeze-dried Jynneos vaccine and EU/US-approved chiku
US FDA approves freeze-dried version of Bavarian Nordic's mpox, smallpox vaccine
05:36pm, Monday, 31'st Mar 2025
Denmark's Bavarian Nordic said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its mpox and smallpox vaccine.
Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine
04:38pm, Monday, 31'st Mar 2025
COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS® (Smallpo
Bavarian Nordic A/S – Notice Convening Annual General Meeting
07:00am, Wednesday, 12'th Mar 2025
COPENHAGEN, Denmark, March 12, 2025 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held
COPENHAGEN, Denmark, March 7, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has validated the marketing authorization
Bavarian Nordic A/S (BVNKF) Q4 2024 Earnings Call Transcript
02:05pm, Wednesday, 05'th Mar 2025
Bavarian Nordic A/S (OTCPK:BVNKF) Q4 2024 Earnings Conference Call March 5, 2025 8:00 AM ET Company Participants Rolf Sass Sorensen - Head, Investor Relations Paul Chaplin - Chief Executive Officer He
COPENHAGEN, Denmark, March 5, 2025 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding man
Bavarian Nordic Publishes Annual Report 2024
01:50am, Wednesday, 05'th Mar 2025
Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million. Two new early-stage pipeline programs, Lyme disease and Epstein-Barr Virus (EBV), introduced.
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older
05:27pm, Friday, 14'th Feb 2025
COPENHAGEN, Denmark, February 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Food and Drug Administration (FDA) has approved VIMKUNYA™ (Chikungunya Vaccine, Recombinant)
Bavarian Nordic – Completion of Share Buy-Back Program
02:31pm, Friday, 31'st Jan 2025
COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 9, 2025, has now been completed, reach
COPENHAGEN, Denmark, November 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding
